The presentations, titled Pharmacokinetics and Pharmacodynamics of Linaprazan Glurate after Multiple Oral Doses up to 14 Days in Healthy Subjects and Optimized Biopharmaceutical and Pharmacokinetic Properties of a Linaprazan Glurate Tablet Formulation to Be Used in Phase 3, held at the international conference Digestive Disease Week in San Diego were held by Dr Kajsa Larsson, Chief Medical Officer at Cinclus Pharma.
 
The first presentation showed data on linaprazan glurate's capacity to inhibit hydrochloric acid production in the stomach and keep the degree of acid under very good control. Six different dose levels were studied in healthy subjects during 14 days of treatment. Already after the first dose, a good effect was seen and within 90 minutes, the two highest doses gave continuous acid control with a pH>4.0 in the stomach >90% of the time. At full effect, the two highest doses led to acid control with pH>5.0 more than 80% of the time.
 
The second presentation showed data on the optimized tablet formulation for linaprazan glurate that has been developed for the Phase III studies and an upcoming commercialization. The new formulation leads to an approximate doubling of the bioavailability compared to the formulation used in previous studies.
 
"The data we present show that the new linaprazan glurate formulation has very good pharmacokinetic properties and provides both a very rapid and powerful acid inhibition in the stomach. The results are promising for the first Phase III study planned later this year," said Kajsa Larsson, Chief Medical Officer at Cinclus Pharma.
 
“It is gratifying to present further positive data on linaprazan glurate's ability to inhibit acid production ahead of our Phase III studies and an upcoming commercialization. We see great market potential for the next generation drugs for acid-related diseases that have a unique ability to improve the quality of life for patients with the more severe forms of eGERD," said Christer Ahlberg, CEO of Cinclus Pharma.